Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> MutationCaroline Robert, Paolo A. Ascierto, Georgina V. Long et al.|New England Journal of Medicine|2014Cited by 5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab TherapyPaolo A. Ascierto, Victoria Atkinson, Georgina V. Long et al.|JAMA Oncology|2018Cited by 345
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced MelanomaCaroline Robert, Victoria Atkinson, Georgina V. Long et al.|Journal of Clinical Oncology|2020Cited by 226
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline ChemotherapyHenri Roché, Hervé Curé, Rana Ezzeddine et al.|Journal of Clinical Oncology|2007Cited by 225
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trialLucia Del Mastro, Francesco Cognetti, Sabino De Placido et al.|The Lancet|2015Cited by 201